Comments on: Clinical Trials on Kanchanara Guggulu: Thyroid Nodule and Lipoma Evidence Review

By: Laura Mitchell

Laura Mitchell — Tue, 22 Sep 2026 23:07:53 +0000

Overall the article does a good job of balancing optimism with honesty about the evidence gaps.

By: Susan Clark

Susan Clark — Sat, 19 Sep 2026 13:42:22 +0000

I found the section on Trikatu’s role in boosting bioavailability particularly useful for understanding why the formula works.

By: Matthew Green

Matthew Green — Wed, 16 Sep 2026 13:05:26 +0000

For someone with a thyroid nodule getting a repeat ultrasound at three months seems like a sensible way to track progress.

By: Vikram Sharma

Vikram Sharma — Tue, 15 Sep 2026 16:41:32 +0000

The claim about methodology reducing inflammation in two weeks seems optimistic. My experience was more like four months before any noticeable change.

By: Rakesh Mukherjee

Rakesh Mukherjee — Mon, 14 Sep 2026 17:37:08 +0000

In reply to Rohit Bansal. I asked my vaidya the same question about RCT. He said constitution matters more than standard dose.

By: Laura Anderson

Laura Anderson — Mon, 14 Sep 2026 16:02:08 +0000

Where is the evidence for the kanchanara dosage recommended here? I could not find any peer-reviewed backing in the Indian Journal of Ayurveda for these specific numbers.

By: Lisa Taylor

Lisa Taylor — Mon, 14 Sep 2026 15:17:38 +0000

will try clinical trial now

By: Shruti Banerjee

Shruti Banerjee — Mon, 14 Sep 2026 12:44:27 +0000

@Rakesh The formulation type matters a lot for methodology. Churna vs capsule vs kashayam gave me different results.

By: Michael Walker

Michael Walker — Sun, 13 Sep 2026 16:20:37 +0000

I asked my vaidya the same question about methodology. He said constitution matters more than standard dose.

By: Kevin Martin

Kevin Martin — Sun, 13 Sep 2026 14:38:13 +0000

The comparative study against watchful waiting shows some promise yet the lack of blinding makes me cautious.